Search
Avelumab
go.drugbank.com/drugs/DB11945ApprovedInvestigational[A261496] Avelumab was first approved by the FDA on March 23, 2017. … [A261496] On September 18 and December 18 of the same year, it was also granted approval by EMA [L48126] and Health Canada,[L48171] respectively.
Liraglutide
go.drugbank.com/drugs/DB06655ApprovedInvestigational[Label,A6932] Liraglutide is 97% similar to native human GLP-1, differing primarily by substituting arginine for lysine at position 34. … [A6932] Liraglutide is made by attaching a C-16 fatty acid (palmitic acid) with a glutamic acid spacer on the remaining lysine residue at position 26 of the peptide precursor.
Hepatitis A Vaccine
go.drugbank.com/drugs/DB10989ApprovedInvestigationalagainst the disease caused by infection with this virus. … [A199182] Known by several trade names, such as Havrix and Twinrix, the Hepatitis A vaccine has been formulated for immunization against hepatitis A virus (HAV) infection and safely confers strong protection
Rizatriptan
go.drugbank.com/drugs/DB00953ApprovedInvestigationalRizatriptan is a second-generation triptan and a selective 5-HT1B and 5-HT1D receptor agonist. Used in the treatment of migraines, rizatriptan was first approved in the US in 1998. Rizatriptan is available in oral tablets, orally disinte...
Technetium Tc-99m pertechnetate
go.drugbank.com/drugs/DB09314ApprovedInvestigationalFollowing intravenous injection, single photon emission computed tomography (SPECT) is performed to detect the gamma ray emmitted by the decay of Technetium-99m to Technetium-99.
Rasburicase
go.drugbank.com/drugs/DB00049ApprovedInvestigationalRasburicase is a recombinant urate-oxidase enzyme produced by a genetically modified <i>Saccharomyces cerevisiae</i> strain.
Noxytiolin
go.drugbank.com/drugs/DB13838ApprovedLocal antibacterial that probably acts by releasing formaldehyde in aqueous solutions.
Sonidegib
go.drugbank.com/drugs/DB09143ApprovedInvestigationalSonidegib is a Hedgehog signaling pathway inhibitor (via smoothened antagonism) developed as an anticancer agent by Novartis. It was FDA approved in 2015 for the treatment of basal cell carcinoma.
Omacetaxine mepesuccinate
go.drugbank.com/drugs/DB04865ApprovedInvestigationalWithdrawnIn November 2006, omacetaxine mepesuccinate, for the treatment of CML, was granted Fast Track designation by the FDA.
PI-166
go.drugbank.com/drugs/DB05859ExperimentalPI-166 is a small organic compound with specific avidity to liver cancer cells. It has demonstrated the ability to reduce the growth of rat hepatomas, which is like human hepatomas, are resistant to established anti-cancer agents.